Collegium Pharmaceutical’s (COLL) Buy Rating Reaffirmed at HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLLGet Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $50.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 51.93% from the company’s current price.

A number of other brokerages also recently commented on COLL. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday. Finally, Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $43.80.

Check Out Our Latest Analysis on Collegium Pharmaceutical

Collegium Pharmaceutical Stock Performance

COLL opened at $32.91 on Friday. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm has a 50 day moving average of $30.56 and a two-hundred day moving average of $34.05. Collegium Pharmaceutical has a 12-month low of $28.39 and a 12-month high of $42.29. The firm has a market capitalization of $1.06 billion, a PE ratio of 14.19 and a beta of 0.82.

Institutional Trading of Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its stake in Collegium Pharmaceutical by 124.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 792 shares in the last quarter. CWM LLC raised its stake in Collegium Pharmaceutical by 97.5% in the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Collegium Pharmaceutical during the third quarter worth $72,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Collegium Pharmaceutical by 61.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 6,196 shares of the specialty pharmaceutical company’s stock valued at $239,000 after buying an additional 2,352 shares during the last quarter.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Featured Articles

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.